Heart failure is one of the leading causes of illness and death worldwide. For patients with advanced forms (classified as NYHA III–IV), standard treatments are often insufficient. Heart transplantation, although a last resort, is severely limited by the scarcity of donor organs. Fortunately, new cell-based therapies are emerging as a promising alternative to regenerate and restore cardiac function.

What Are iPSC Stem Cells?
The key to this new therapy lies in induced pluripotent stem cells (iPSCs). These cells have the ability to be differentiated in vitro (outside the body) into highly purified cardiomyocytes, the cells that make up the heart muscle. Using iPSC-derived cardiomyocytes is considered an ideal approach for regenerative medicine, aiming to replace lost cardiac tissue.

The First-in-Human Study
Recently, the first-in-human study of direct transplantation of iPSC-derived (allogeneic) cardiomyocytes was completed. The study involved two patients with advanced heart failure (NYHA functional class IV). In May 2019, during open-heart coronary artery bypass grafting (CABG) surgery, both patients received intramyocardial injections of approximately 100 million iPSC-derived cardiomyocytes into the area of infarcted tissue. Afterwards, they followed a one-month immunosuppressive regimen.

Long-Term Results: Safety and Improvement
This study provided the longest-term safety data available to date (up to 48 months) for cardiac regenerative therapy.

Key Safety Aspects:
• No tumors, off-target effects, or serious adverse events were reported. Imaging performed at 48 months on Patient 2 showed no tumor formation in the heart or any other organs.
• Similar to what was observed in animal studies, early arrhythmias (such as atrial fibrillation and non-sustained ventricular tachycardia) were detected in the days following the procedure. However, these arrhythmias were managed (for example, with prophylactic amiodarone) and did not compromise the patients’ hemodynamic stability.
• Improvement in Cardiac Function and Quality of Life: Both patients showed significant improvements, particularly within the 12-month follow-up period.
• Exercise Capacity: Measured using the 6-minute walk distance (6MWD) test, exercise capacity increased significantly. In Patient 2, for example, the distance improved from 180 meters before the transplant to 480 meters after 48 months.

• Left Ventricular Ejection Fraction (LVEF): This is a crucial indicator of the heart’s pumping function. LVEF improved in both patients. Patient 2 saw their LVEF increase from 28% before the transplant to 47% at 48 months.
• Quality of Life (QoL): Measured using the MLHFQ questionnaire, quality of life improved drastically for both patients, with scores indicating significant well-being.
• NYHA Functional Class: Cardiac function improved from Class IV (most severe) to Class II (less severe) within 12 months in both patients, remaining at that level for Patient 2 up to 48 months. A remarkable finding from the scans was that the heart improvement in Patient 2 at 48 months was spatially localized to the areas where the cells had been implanted.

Future Perspectives
In summary, although the study was primarily focused on feasibility and safety, the results demonstrate that the administration of iPSC-derived cardiomyocytes is safe in the long term and is associated with improved cardiac function.
Since the cell transplant was performed simultaneously with revascularization (CABG), it was not possible to completely distinguish the effects of the cells alone. However, the clear demonstration of safety provides strong encouragement to continue developing iPSC-derived cardiomyocytes as a new treatment modality for severe heart failure. Future challenges, which subsequent studies are already addressing, include optimizing immunosuppression and developing less invasive cell delivery methods.

Prepare Your Future with EternaCell
These extraordinary results highlight the potential of iPSC-based stem cell therapies.
But there is one crucial element: the quality and vitality of the cells being used..
EternaCell gives you the opportunity to preserve your young, healthy cells today, protecting them from aging and environmental damage. Through a simple blood draw, we store your mononuclear cells under optimal conditions for at least 20 years, ensuring you future access to the most advanced regenerative therapies.
When these cardiac therapies become widely available, your personal cells will already be on hand, ready to be reprogrammed into iPSCs and used for fully compatible treatments, with no risk of rejection.
Investing in cell preservation today means securing the best therapeutic options for tomorrow. With the highest industry standards (FACT-NetCord, GMP) and the support of our partner Swiss Stem Cells Biotech, EternaCell represents the safest and most innovative choice to protect your biological future.
Learn more about how to preserve your cells for tomorrow: www.eternacell.ch

Source:
He Zhang, Qian Wang, Xiyu Zhu, Yunxing Xue, Jiaxian Wang, Dongjin Wang,
Reviving Hearts, Restoring Lives: Long-Term Outcomes of Allogeneic iPSC-Cardiomyocytes
Transplantation for Advanced Heart Failure Patients, ACC: Basic to Translational Science, Volume
10, Issue 3, 2025, Pages 253-255, ISSN 2452-302X, https://doi.org/10.1016/j.jacbts.2025.01.007.